WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
Recruiting · Not applicable · NCT04701684
Conditions: Stroke, Acute
At a glance
- Research payments reported, 2025
- $3,862
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 594
About the trial
- Sponsor
- Philips Clinical & Medical Affairs Global
- Tested
- Direct to Angio Suite (DTAS) Philips' CBCT triage (device), Conventional CT/MR triage (procedure)
- Dates
- Started 2021-06-23; completion 2027-04-01
- Results posted
- Not yet
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Philips North America LLC reported $3,862 in research payments for this study in 2025 (2 payments).
Products named: Health Integration, Igt Systems Undivided
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baptist Health Research Center $3,862
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.